The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 88-102

  Khosravan, Reza ^a   Grabowski, Brian A ^a   Mayer, Michael D ^a   Wu, Jing Tao ^a   Joseph Ridge, Nancy ^a   Vernillet, Laurent ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Febuxostat; Hepatic impairment; Pharmacodynamics; Pharmacokinetics; Xanthine oxidase

Indexed keywords

FEBUXOSTAT; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIVER DISEASE; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; STEADY STATE; URIC ACID BLOOD LEVEL; URINARY FREQUENCY;

ADMINISTRATION, ORAL; ADULT; BIOTRANSFORMATION; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; THIAZOLES; XANTHINE OXIDASE;

EID: 29644447615     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005282634     Document Type: Article

References (30)

1. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-3007.
2. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia, Pa: W. B. Saunders Company; 2001:1339-1376.
3. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.
4. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-1587.
5. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk of subsequent coronary heart disease: the Meharry-Hopkins Study. Arch Intern Med. 1997;157:1436-1440.
6. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848-1855.
7. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sciences. 2005;76:1835-1847.
8. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993;241:183-188.
9. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxides inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993;250:455-460.
10. Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol. 1999;104:307-319.
11. Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. Arthritis Rheum. 2002;46:289.
12. Kaniatani N, Fujimori S, Hada T, et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/ xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum. 2003;48:S530.
13. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides, Nucleotides Nucleic Acids. 2004;23:1111-1116.
14. Becker MA, Schumacher HR, Wortmann RL, et al. A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout [abstract]. Arthritis Rheum. 2004;50:4103-4104.
15. Kondo S, Nishimura S, Mochizuki T, et al. Metabolic fate of [14C]-TEI-6720, a novel xanthine oxidase inhibitor: tissue distribution after oral administration in rats, protein binding and metabolism in vivo and in vitro [abstract]. Drug Metab Review. 1995;18:56.
16. Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in human [abstract]. Drug Metab Review. 2000;32:269.
17. Khosravan R, Mayer M, Grabowski B, Vernillet L, Wu J-T, Joseph-Ridge N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase-effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety [abstract]. Arthritis Rheum. 2004;50:S337.
18. Khosravan R, Grabowski B, Mayer M, Wu J, Joseph-Ridge, Vernillet L. Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat [abstract]. J Clin Pharmacol. In press.
19. Pugh RNH, Murry-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg. 1973;60:646-649.
20. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol. 1989;24:269-276.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Macdonald JI, Wallace SM, Mahachai V, Verbeeck RK. Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. Eur J Clin Pharmacol. 1992;42:471-474.
23. Sonne J, Andreasen PB, Loft S, Dossing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology. 1990;11:951-956.
24. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997;62:272-278.
25. Hildebrandt R, Gundert-Remy U, Raedsch R, Sieg A, Stiehl A. Biliary excretion of mezlocillin in patients with hepatic disease. Int J Clin Pharmacol Ther. 1995;33:384-387.
26. Mayer MD, Khosravan R, Vernillet L, Wu J, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. A J Ther. 2005;12:22-34.
27. Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease. 4th ed. Philadelphia, Pa: W. B. Saunders; 1989:1355-1360.
28. Kountouras J, Magoula I, Tsapas G, Liatsis I. The effect of mannitol and secretin on the biliary transport of urate in human. Hepatology. 1996;23:229-233.
29. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. Effects of age and gender on febuxostat pharmacokinetics, pharmacodynamics, and safety in healthy subjects [abstract]. Clin Pharmacol Ther. 2005;77:P50.
30. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on febuxostat pharmacokinetics and pharmacodynamics in healthy subjects [abstract]. Clin Pharmacol Ther. 2005;77:P50. I